HCW Biologics Inc. (HCWB) Stock Forecast
HCWB analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $48.00 average of analyst targets
- Upside to target
- +3,771.0% from the latest close
- Next earnings
- November 13, 2026
- 52-week range
- $1.17 – $23.76
HCWB analyst ratings
1 analystsNumber of analysts at each rating.
HCWB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
HCWB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$8.10 | −$8.10 | −$8.10 | −$12.12 | +33.2% | 1 |
| Current fiscal year (2026) | −$28.32 | −$28.32 | −$28.32 | −$63.78 | +55.6% | 1 |
| Next fiscal year (2027) | −$6.30 | −$6.30 | −$6.30 | −$28.32 | +77.8% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
HCWB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | −100.0% | 1 |
| Current fiscal year (2026) | $6.7M | $6.7M | $6.7M | +12,216.1% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | −100.0% | 1 |
HCWB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
HCWB revenue: reported and forecast
HCWB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.08 | −$1.08 | −$1.08 | −$1.08 | −$8.10 | +650.0% | 0 up · 1 down |
| Current fiscal year (2026) | −$2.88 | −$2.88 | −$2.88 | −$2.88 | −$28.32 | +883.3% | 0 up · 1 down |
| Next fiscal year (2027) | −$2.64 | −$2.64 | −$2.64 | −$2.64 | −$6.30 | +138.6% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
HCWB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; HCWB beat in 2 of 11.
What analysts expect from HCWB
1 analysts cover HCW Biologics; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $48.00, 3,771.0% above the latest close of $1.24. Analysts expect earnings of −$28.32 per share for 2026, +55.6% from a year earlier. For 2027 the average estimate is −$6.30 per share. HCW Biologics beat the EPS estimate in 2 of the last 11 quarters.
Related: HCWB income statement, HCWB key metrics, HCWB chart. See the HCWB stock overview for the latest quote and news.
HCWB forecast FAQ
What is HCW Biologics's price target?
The average analyst price target for HCW Biologics is $48.00, 3,771.0% above the latest close of $1.24.
Is HCW Biologics a buy, hold or sell?
Of 1 analysts covering HCW Biologics, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is HCW Biologics's EPS forecast?
Analysts forecast −$28.32 per share for 2026 (range −$28.32 to −$28.32); for 2027 the estimate is −$6.30.
What is HCW Biologics's revenue forecast?
The average revenue estimate for 2026 is $6.7 million, growth of 12,216.1%.
When does HCW Biologics report earnings?
HCW Biologics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
Does HCW Biologics usually beat earnings estimates?
HCW Biologics reported EPS at or above the analyst estimate in 2 of the last 11 quarters.